Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
6 Results for "
intravitreally
" in MedChemExpress (MCE) Product Catalog:
Products (6)
6 Results for "intravitreally" in MCE Product Catalog:
Cat. No.: HY-153484A
CAS No.: 849758-52-7
Target:
Research Areas:
Bevasiranib sodium is a siRNA that targets and silences VEGF-A. Bevasiranib sodium activates the RNA-induced silencing complex to degrade VEGF-A mRNA, mediates TLR3-related inhibition of choroidal neovascularization, and triggers RNA interference-mediated gene silencing through endogenous eukaryotic RNAi mechanisms. After intravitreal injection, Bevasiranib sodium distributes to various ocular tissues and resists degradation by intraocular nucleases, reducing choroidal neovascularization area and alleviating vascular leakage. Bevasiranib sodium can be used in research related to macular degeneration .
Cat. No.: HY-16387
CAS No.: 854514-88-8
PF-00337210 is a potent and selective inhibitor of VEGFRs, designed for treating age-related macular degeneration via intravitreal injection. The formulation strategy focused on developing an ophthalmic solution that would precipitate upon injection into the vitreous, ensuring sustained drug delivery. Challenges included maintaining low dosing volumes, selecting safe excipients for intravitreal use, and addressing the drug's unique physicochemical properties. The final formulation, an isotonic solution in a citrate-buffered vehicle with NaCl, demonstrated stability, potency, and recovery through intravitreal dosing syringes. It formed a depot upon injection into vitreous humor, representing a novel nonpolymeric in situ-forming depot formulation for intravitreal drug delivery .
Cat. No.: HY-153484
CAS No.: 959961-96-7
Target:
Research Areas:
Bevasiranib is a siRNA that targets and silences VEGF-A. Bevasiranib activates the RNA-induced silencing complex to degrade VEGF-A mRNA, mediates TLR3-related inhibition of choroidal neovascularization, and triggers RNA interference-mediated gene silencing through endogenous eukaryotic RNAi mechanisms. After intravitreal injection, Bevasiranib distributes to various ocular tissues and resists degradation by intraocular nucleases, reducing choroidal neovascularization area and alleviating vascular leakage. Bevasiranib can be used in research related to macular degeneration .
Cat. No.: HY-P991030
CAS No.: 2839527-15-8
Synonyms: OG-2072
Target:
Research Areas:
Cat. No.: HY-P992142
CAS No.: 3050549-24-8
Synonyms: ANX-007
Target:
Research Areas:
Cat. No.: HY-P992126
CAS No.: 3059389-31-7
Synonyms: EYE-103; MK-3000
Target:
Research Areas:
Remigromig (EYE-103; MK-3000) is a humanized dual-target monoclonal antibody that targets LRP5 and FZD4. Remigromig activates the Wnt/β-catenin signaling pathway by mimicking the natural ligand Norrin, induces tight junction formation and restores blood-retinal barrier function. Administered via intravitreal injection, Remigromig reduces retinal vascular leakage, and demonstrates improvements in best-corrected visual acuity and reductions in retinal thickness in studies of diabetic macular edema. Remigromig can be used for research related to macular degeneration .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
